Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug562 | Bromhexine Hydrochloride Tablets Wiki | 0.58 |
| drug295 | Arbidol Hydrochloride Granules Wiki | 0.58 |
| drug3504 | Tradipitant Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4111 | sofosbuvir Wiki | 0.58 |
| drug1705 | Internet-connected computer tablet Wiki | 0.58 |
| drug2823 | Recombinant Human Interferon α2b Spray Wiki | 0.58 |
| drug1687 | Interferon beta-1b Wiki | 0.41 |
| drug981 | Daclatasvir Wiki | 0.41 |
| drug1684 | Interferon Beta-1B Wiki | 0.33 |
| drug1872 | Lopinavir/ritonavir Wiki | 0.18 |
| drug2505 | Placebo Wiki | 0.03 |
Navigate: Correlations HPO
There are 3 clinical trials
A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2019-n-CoV infection compared with to lopinavir/ ritonavir
Description: Time to negative NPS 2019-n-CoV RT-PCR
Measure: Time to negative NPS Time: Up to 1 monthDescription: Time to negative saliva 2019-n-CoV RT-PCR
Measure: Time to negative saliva Time: Up to 1 monthDescription: Time to NEWS of 0
Measure: Time to clinical improvement Time: Up to 1 monthDescription: Length of hospitalisation
Measure: Hospitalisation Time: Up to 1 monthDescription: 30-day mortality
Measure: Mortality Time: Up to 1 monthDescription: Cytokine/ chemokine changes
Measure: Immune reaction Time: up to 1 monthDescription: Adverse events during treatment
Measure: Adverse events Time: up to 1 monthDescription: Time to negative NPS, saliva, urine and stool 2019-n-CoV RT-PCR
Measure: Time to negative all clinical specimens Time: up to 1 monthSofosbuvir with and without ribavirin in treatment of COVID 19 Egyptian patients
Description: The total number of patients with response to treatment
Measure: Number of patients with response to treatment Time: 1 monthAs of 1 July 2020, more than 10 million people been confirmed to have infected by SARS-CoV-2, resulting in more than 500,000 deaths. No specific antiviral treatment for the SARS-CoV-2 is currently available, but existing medication could be repurposed. The investigators therefore propose to conduct an open-label randomized controlled trial on a short course of interferon β-1b and ribavirin combination treatment for patients hospitalized for COVID-19 infection.
Description: Time to complete alleviation of symptoms as defined by NEWS2 of 0 maintained for 24 hours
Measure: Clinical symptoms alleviation Time: 7 daysDescription: Length of hospitalisation
Measure: Hospitalisation Time: 14 daysDescription: Time to negative nasopharyngeal swab and throat saliva viral load by RT-PCR
Measure: Time to negative viral load Time: 7 daysDescription: Cytokine/ chemokine changes
Measure: Inflammatory changes Time: 7 daysDescription: One month mortality rate
Measure: Mortality Time: 30 daysDescription: Adverse events and serious adverse events within 30 days of treatment
Measure: Adverse events and serious adverse events Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports